HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $80.00 price objective on the biotechnology company’s stock.
Other research analysts have also issued research reports about the company. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Sanford C. Bernstein reduced their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. Citigroup cut their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, November 27th. Piper Sandler reduced their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $43.33.
Check Out Our Latest Report on Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Stock Down 3.6 %
Insider Buying and Selling at Arrowhead Pharmaceuticals
In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,850 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the sale, the director now owns 36,740 shares in the company, valued at $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now owns 272,122 shares of the company’s stock, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 146,473 shares of company stock valued at $2,937,847 in the last ninety days. Company insiders own 4.50% of the company’s stock.
Institutional Trading of Arrowhead Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. R Squared Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $38,000. Values First Advisors Inc. bought a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $52,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 788 shares during the last quarter. KBC Group NV raised its position in Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 1,644 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $149,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Recommended Stories
- Five stocks we like better than Arrowhead Pharmaceuticals
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Bloom Energy: Powering the Future With Decentralized Energy
- The Risks of Owning Bonds
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Stock Dividend Cuts Happen Are You Ready?
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.